Effect of topical oxytocin gel on vaginal mucosa in postmenopausal Egyptian women : a clinical randomized trial
© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Vaginal atrophy is common after menopause and is often linked to sexual dysfunction, particularly dyspareunia.
AIM: The study aimed to investigate the effect of intravaginally applied oxytocin on expressions of vaginal atrophy.
METHODS: Fifty postmenopausal women aged 47 to 66 years with vaginal atrophy participated in this double-blinded placebo-controlled study. The women were randomized to intravaginal treatment with either gel with 600 IU/mL of oxytocin (oxytocin group) or gel alone (control group) once daily for 2 weeks. The gel consisted of hypromellose, pH 3.8 (Vagovital).
OUTCOMES: The color of the vaginal mucosa, the vaginal pH, and the cytology of vaginal epithelial cells were investigated before and after treatment.
RESULTS: The color of the vaginal mucosa shifted from pale to red in all 25 patients treated with oxytocin but only in 4 patients in the control group (P < .001). There was a significant decrease in intravaginal pH in the oxytocin group and the control group, with the delta value being significantly greater in the oxytocin group than in the control group (P < .001). The vaginal maturation index increased significantly (P < .001) in the oxytocin group but not in the control group.
CLINICAL IMPLICATIONS: Topical oxytocin gel offers an effective solution to the sexual dysfunction that is related to vaginal atrophy after menopause.
STRENGTHS AND LIMITATIONS: Strengths include studying different outcomes of applying the oxytocin gel for vaginal atrophy. Limitations include the small-scale population with a relatively short duration of treatment (2 weeks).
CONCLUSION: Intravaginal treatment with a gel containing 600 IU/mL of oxytocin effectively counteracts physical expressions of vaginal atrophy.
TRIAL REGISTRATION: ClinicalTrials.gov (NCT05275270; https://clinicaltrials.gov/ct2/show/NCT05275270).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
The journal of sexual medicine - 20(2023), 2 vom: 14. Feb., Seite 177-183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Moussa, Asem [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
50-56-6 |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 27.02.2023 published: Print ClinicalTrials.gov: NCT05275270 Citation Status MEDLINE |
|---|
| doi: |
10.1093/jsxmed/qdac021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35273681X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35273681X | ||
| 003 | DE-627 | ||
| 005 | 20231226054415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jsxmed/qdac021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM35273681X | ||
| 035 | |a (NLM)36763919 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Moussa, Asem |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of topical oxytocin gel on vaginal mucosa in postmenopausal Egyptian women |b a clinical randomized trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 27.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT05275270 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Vaginal atrophy is common after menopause and is often linked to sexual dysfunction, particularly dyspareunia | ||
| 520 | |a AIM: The study aimed to investigate the effect of intravaginally applied oxytocin on expressions of vaginal atrophy | ||
| 520 | |a METHODS: Fifty postmenopausal women aged 47 to 66 years with vaginal atrophy participated in this double-blinded placebo-controlled study. The women were randomized to intravaginal treatment with either gel with 600 IU/mL of oxytocin (oxytocin group) or gel alone (control group) once daily for 2 weeks. The gel consisted of hypromellose, pH 3.8 (Vagovital) | ||
| 520 | |a OUTCOMES: The color of the vaginal mucosa, the vaginal pH, and the cytology of vaginal epithelial cells were investigated before and after treatment | ||
| 520 | |a RESULTS: The color of the vaginal mucosa shifted from pale to red in all 25 patients treated with oxytocin but only in 4 patients in the control group (P < .001). There was a significant decrease in intravaginal pH in the oxytocin group and the control group, with the delta value being significantly greater in the oxytocin group than in the control group (P < .001). The vaginal maturation index increased significantly (P < .001) in the oxytocin group but not in the control group | ||
| 520 | |a CLINICAL IMPLICATIONS: Topical oxytocin gel offers an effective solution to the sexual dysfunction that is related to vaginal atrophy after menopause | ||
| 520 | |a STRENGTHS AND LIMITATIONS: Strengths include studying different outcomes of applying the oxytocin gel for vaginal atrophy. Limitations include the small-scale population with a relatively short duration of treatment (2 weeks) | ||
| 520 | |a CONCLUSION: Intravaginal treatment with a gel containing 600 IU/mL of oxytocin effectively counteracts physical expressions of vaginal atrophy | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov (NCT05275270; https://clinicaltrials.gov/ct2/show/NCT05275270) | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a oxytocin | |
| 650 | 4 | |a postmenopause | |
| 650 | 4 | |a vaginal mucosa | |
| 650 | 4 | |a vaginal pH | |
| 650 | 4 | |a vaginal smear | |
| 650 | 7 | |a Oxytocin |2 NLM | |
| 650 | 7 | |a 50-56-6 |2 NLM | |
| 700 | 1 | |a Moberg, Kerstin Uvnäs |e verfasserin |4 aut | |
| 700 | 1 | |a Elgrahy, Ismael |e verfasserin |4 aut | |
| 700 | 1 | |a Elsayied, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Abdel-Rasheed, Mazen |e verfasserin |4 aut | |
| 700 | 1 | |a Farouk, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Hany |e verfasserin |4 aut | |
| 700 | 1 | |a Meshaal, Hadeer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of sexual medicine |d 2004 |g 20(2023), 2 vom: 14. Feb., Seite 177-183 |w (DE-627)NLM159924006 |x 1743-6109 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:2 |g day:14 |g month:02 |g pages:177-183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jsxmed/qdac021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 2 |b 14 |c 02 |h 177-183 | ||